Evidence map›Paper›PMID 34585951›Full record

ArticleMicrobiology spectrum2021

Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.

Lloyd Tanner, Gabriel T Mashabela, Charles C Omollo, Timothy J de Wet, Christopher J Parkinson, Digby F Warner, Richard K Haynes, Lubbe Wiesner

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Development of Human Cell-BasedFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lloyd TannerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Towngrid.7836.a, Cape Town, South Africa.ORCID 0000-0003-0626-9820
Gabriel T MashabelaSAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Towngrid.7836.a, Cape Town, South Africa.
Charles C OmolloSAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Towngrid.7836.a, Cape Town, South Africa.
Timothy J de WetSAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Towngrid.7836.a, Cape Town, South Africa.
Christopher J ParkinsonSchool of Biomedical Sciences, Charles Sturt Universitygrid.1037.5, Orange, New South Wales, Australia.
Digby F WarnerSAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Towngrid.7836.a, Cape Town, South Africa.ORCID 0000-0002-4146-0930
Richard K HaynesCentre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.ORCID 0000-0001-8554-1823
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Towngrid.7836.a, Cape Town, South Africa.ORCID 0000-0002-9070-8699
South African Medical Research Council · ZAUniversity of Cape Town · ZACharles Sturt University · AUNorth-West University · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic repertoire for tuberculosis (TB) remains limited despite the existence of many TB drugs that are highly active in

Indexed as

AnimalsAntitubercular AgentsCell SurvivalDrug SynergismHumansMacrophagesMiceMoxifloxacinMycobacterium tuberculosisRifampinTuberculosisAntitubercular AgentsMoxifloxacinRifampinartemisininintracellular accumulationintracellular efficacymacrophagesphenoxazinesynergism tuberculosisTB chemotherapy

Identifiers

PMID34585951
PMCPMC8557888
OpenAlexW3203490617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.